Declaration of competing interest JS has received research grants by the German Federal Ministry of Education and Research (BMBF), the Medical Faculty of the University of Cologne, Basilea Pharmaceutica, Noscendo and Scynexis; has received speaker honoraria by AbbVie, Akademie für Infektionsmedizin e.V., Forum für medizinische Fortbildung GmbH, Hikma, Lilly, Mundipharma, Pfizer, VITIS GmbH; has been a consultant to or participated on advisory boards of AiCuris, Alvea, Basilea, Kite-Gilead, Micron Research, Mundipharma, Shionogi all outside the submitted work. He received travel support from Page Medical, German Society for Infectious Diseases and Meta-Alexander Foundation. LY no conflicts declared. CS no conflicts declared. KGIM has received honoraria for lectures from Takeda, IQVIA and BioNTech, has received a Research Grant from Norwegian Regional Health authorities, West, grant nr F12626 and is a member of an advisory board on committee for National vaccination programs, Norwegian Public Health Institute. AJCS no conflicts declared. ERR no conflicts declared. JMM no conflicts declared. IVM no conflicts declared. IP no conflicts declared. TW no conflicts declared. BZ no conflicts declared. MA has received research grants from Pfizer and Gilead; contributed to educational activities organized/supported by Pfizer, Roche, Gilead, GSK, Moderna and Sanofi. All honoraria from these activities are paid to the Institution. UB no conflicts declared. SH no conflicts declared. JSG has received speaker honoraria from AstraZeneca, Gilead, Pfizer, and Menarini, and has been a member of an advisory board for Pfizer, outside of the submitted work. JJ no conflicts declared. LT no conflicts declared. MZ received honoraria for lecturing courses by Pfizer Malaysia; was an employee with AiCuris AG and is now an employee with DEBRA Research gGmbH. AC no conflicts declared. LMB no conflicts declared. JG no conflicts declared. SCM reports grants from the German Center for Infection Research, from the Else-Kröner-Fresenius Stiftung, lecture and speaker honoraria from Akademie für Infektionsmedizin e.V., AstraZeneca, GSK, Octapharma, and Pfizer; all outside of the submitted work. JAN no conflicts declared. JN no conflicts declared. RS reports grants from the German Center for Infection Research and the Ministry of Culture and Science of the State of North Rhine-Westphalia, lecture and speaker honoraria from Akademie für Infektionsmedizin e.V., Ärztliche Akademie für medizinische Fort- und Weiterbildung in Nordrhein, Forum für medizinische Fortbildung GmbH, Infektio Saar Netz, Hikma, Mundipharma and Pfizer and travel support from the European Confederation of Medical Mycology (ECMM), International Society for Human and Animal Mycology (ISHAM), Page Medical and Pfizer; all outside of the submitted work. JFI has received research grants by the Instituto de Salud Carlos III, Ministry of Science. Spain; has received grants or research contracts from Laboratorios Faes, Normon, Pfizer, Italfarmaco, GSK, Prestige; has been a consultant or has received speaker honoraria from Faes, Normon, Cinfa, Mundipharma, Abbott, Novartis and docency colaborations from AbbVie. RN no conflicts declared. CG no conflicts declared. GS no conflicts declared. AGL no conflicts declared. PWGM has received honoraria and/or grant funding from Gilead, Janssen, MSD, ViiV Healthcare, GSK and AstraZeneca, outside of the submitted work. CL no conflicts declared. AH no conflicts declared. KL no conflicts declared. SMK has received grants from Pfizer, MSD, Huvepharma, AiCuris, Astra Zeneca, Mylan, Janssen pharma. HG no conflicts declared. SKS no conflicts declared. FK no conflicts declared. MP no conflicts declared. PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM), the State of North Rhine-Westphalia and the Dr. Heinz Lux-Stiftung; consulting fees Ambu GmbH, Gilead Sciences, infill healthcare communication GmbH, Mundipharma Research Limited, Noxxon N.V. and Pfizer Pharma; honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Jazz Pharmaceuticals Germany GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Scilink Comunicación Científica SC, streamedup! GmbH, University Hospital and LMU Munich and VITIS GmbH; participation on an advisory board from Ambu GmbH, Gilead Sciences, Mundipharma Research Limited and Pfizer Pharma; a filed patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from AbbVie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, AbbVie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi; payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or advisory board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group.
PubMed
